Mural Oncology 报告季度亏损，但在专注于癌症免疫治疗的情况下，其股价上涨。 Mural Oncology reports quarterly loss, yet its stock rises amid focus on cancer immunotherapy.

癌症药物开发商Mural肿瘤学报告说,每季度每股损失2.01美元,分析师的预期略为缺失。 Mural Oncology, a cancer drug developer, reported a quarterly loss of $2.01 per share, slightly missing analyst expectations. 尽管收入少了,但该公司的股票在交易期间升至3.80美元。 Despite the earnings miss, the company's stock rose to $3.80 during trading. 壁画瘤学公司的市值为6468万美元,专注于免疫疗法治疗,包括其主要候选产品, nemvaleukin alfa,用于黑色素瘤和卵巢癌. Mural Oncology, with a market cap of $64.68 million, is focused on immunotherapy treatments, including its lead product candidate, nemvaleukin alfa, for melanoma and ovarian cancer.